ArticleThoracic cancer2026
Lobe-Specific Versus Systematic Lymph Node Dissection in Clinical Stage I Non-Small Cell Lung Cancer: A Propensity Score-Matched Analysis Based on the 8th Edition of the TNM Stage Classification.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal extent of lymph node dissection (LND) in early-stage non-small cell lung cancer (NSCLC) remains controversial. This study aimed to compare perioperative and oncological outcomes between lobe-specific LND (LSD) and systematic LND (SND) in patients with clinical stage I NSCLC based on the 8th edition of the TNM classification.
methodsWe retrospectively analyzed 390 patients with clinical stage I NSCLC who underwent lobectomy with LND between 2010 and 2020. Patients with tumors in the right middle lobe or left lingular segment were excluded. Propensity score matching (PSM; 1:1 nearest-neighbor matching) was performed using clinical and radiological covariates, yielding 140 matched patients in each group. Perioperative outcomes, postoperative complications (Clavien-Dindo grade ≥ II, with postoperative pneumonitis assessed according to CTCAE version 5.0), overall survival (OS), relapse-free survival (RFS), and recurrence patterns were compared.
resultsAfter PSM, the LSD group had significantly shorter operative time, less blood loss, and shorter durations of chest tube placement and postoperative hospital stay than the SND group (all p < 0.05). Postoperative supraventricular tachyarrhythmia occurred more frequently in the SND group (0.7% vs. 7.1%, p = 0.006), whereas other complications were comparable. There were no significant differences in OS or RFS before or after PSM. Recurrence rates and patterns, including ipsilateral lymph node recurrence, were comparable.
conclusionsLSD appears to be an oncologically valid and less invasive alternative to SND in patients with clinical stage I NSCLC. LSD may reduce surgical invasiveness and postoperative morbidity without compromising survival or increasing the risk of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.